Chimeric Receptor T Cells With Trastuzumab in HER2+ Advanced Breast Cancer and Other Solid Tumors
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT06027983 |
Recruitment Status :
Not yet recruiting
First Posted : September 7, 2023
Last Update Posted : October 30, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
HER2+ Advanced Breast Cancer Other Solid Tumors | Drug: Chimeric receptor T-cells + Trastuzumab Drug: Fludarabine and Cyclophosphosphamide | Phase 1 Phase 2 |
Hypothesis
Investigators hypothesize that trastuzumab-mediated cytotoxicity will be augmented by the infusion of autologous chimeric receptor T-cells.
Primary Objectives
- To determine the safety of autologous chimeric receptor T-cells in patients with HER2+ advanced solid tumors
- To determine the clinical benefit rate (CBR) of autologous chimeric receptor T-cells in patients with HER2+ advanced breast cancer
Secondary Objectives
- To determine the expansion and persistence of autologous chimeric receptor T-cells after a single infusion in patients with advanced solid tumors
- To determine anti-tumor efficacy in terms of objective response rate (ORR) and progression-free survival (PFS) of autologous chimeric receptor T-cells in patients with HER2+ advanced breast cancer
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 36 participants |
Allocation: | N/A |
Intervention Model: | Sequential Assignment |
Intervention Model Description: | This is a single arm, open-label, phase Ib safety lead in, followed by phase II study. The phase Ib segment will be carried out in a standard 3+3 dose escalation design. In the phase II, dose expansion will be carried out to a total of 10 patients at recommended phase II dose in both phase Ib and II. Phase Ib: Patients with advanced solid tumors will be enrolled in a 3+3 dose escalation fashion, with projected enrolment of between 6-30 patients to determine RP2D. Once the RP2D is confirmed, the study will proceed to phase II. Phase II: Up to a total of 10 patients with HER2+ advanced breast cancer will be enrolled. For patients who are in Dose level 3 - 5 will require additional Trastuzumab,erythropoietin beta and Lymphodepletion. |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Phase IB Followed by Phase II Study of Trastuzumab Combined With Autologous Chimeric Receptor T Cells in HER2+ Advanced Breast Cancer and Other Solid Tumors |
Estimated Study Start Date : | November 1, 2023 |
Estimated Primary Completion Date : | December 31, 2025 |
Estimated Study Completion Date : | December 31, 2027 |
Arm | Intervention/treatment |
---|---|
Experimental: Chimeric Receptor T-cells
Eligible patients will undergo apheresis prior to cycle 1 therapy. Treatment comprises of trastuzumab followed by chimeric receptor T-cells in cycle 1. During Cycle 2 onwards till disease progression, patients will receive IV or SC trastuzumab only, every 3 weeks. |
Drug: Chimeric receptor T-cells + Trastuzumab
Chimeric receptor T-cells will be administered by infusion. Trastuzumab will be administered intravenously. Drug: Fludarabine and Cyclophosphosphamide 3-day chemotherapy regimen of fludarabine and cyclophosphamide for lymphodepletion
Other Name: Lymphodepletion |
- Time to treatment failure [ Time Frame: 3 years ]defined as the time from the date of study enrolment to the date of the first of the following events: early discontinuation of study therapy, progressive disease, or death due to any cause. Time to treatment failure will be censored at the date of the last follow-up visit for patients who did not discontinue early, who are still alive, and who have not progressed.
- Progression-free survival [ Time Frame: 3 Years ]is defined as the time from the date of study enrolment to the first date of documented disease progression. Progression-free survival will be censored at the date of death for patients who have not had documented disease progression. For patients who are still alive at the time of analysis and who have not had documented disease progression, progression-free survival will be censored at the date of the last follow-up visit.
- Duration of tumour response [ Time Frame: 3 Years ]Among tumor responders, the duration of tumor response is measured from the date of enrolment until the first date of documented disease progression or death due to any cause, whichever occurs first. Duration of tumor response will be censored at the date of the last follow-up visit for tumor responders who are still alive and who have not progressed.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 21 Years to 99 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Patients may be included in the study only if they meet all of the following criteria:
- Age ≥ 21 years.
- Histologically confirmed diagnosis of HER2-positive cancer defined by immunohistochemistry (IHC) to be HER2 IHC3+ or HER2 IHC2+ and FISH positive. If immunohistochemistry is not available, FISH method is acceptable. The HER2 positivities by FISH is determined as FISH amplification ratio positive by institutional guidelines. Tumor subtype for each phase include :
- Phase I: HER2-positive breast or gastric cancer or other treatment-refractory HER2-positive solid tumors
- Phase II : HER2-positive breast carcinoma
- Eastern Cooperative Oncology Group (ECOG) performance status 0-1.
- Has measurable or evaluable disease based on RECIST 1.1 criteria
- Estimated life expectancy of at least 12 weeks.
- Prior lines of therapy:
- HER2-positive breast cancer - patient must have failed at least two lines of anti-HER2 based therapy for advanced/metastatic cancer. Patients with documented relapse while receiving or within 6 months of completion of adjuvant or neoadjuvant trastuzumab for HER2-positive breast cancer will be considered as 1 prior line of therapy.
- HER2-positive gastric cancer - patient must have failed at least one line of anti-HER2 based therapy.
- Other refractory HER2-positive solid tumors (non-breast, non-gastric) - have no standard therapies or have failed or unable to tolerate standard therapies
- Has recovered from acute toxicities from prior anti-cancer therapies
- Left ventricular ejection fraction ≥50%
-
Adequate organ function including the following:
o Bone marrow: Absolute neutrophil (segmented and bands) count (ANC) ≥ 1.5 x 109/L Platelets ≥ 100 x 109/L Haemoglobin ≥ 8 x 109/L
o Hepatic: Bilirubin ≤ 1.5 x upper limit of normal (ULN), ALT or AST≤ 2.5x ULN, (or ≤5 X with liver metastases)
o Renal: Creatinine ≤ 1.5x ULN
- Signed informed consent from patient or legal representative.
- Able to comply with study-related procedures.
- Specific to cohorts 3, 4 and 5 : Patients who have a history of VTE are eligible if as long as they are receiving therapeutic/prophylactic doses of anticoagulation.
Exclusion Criteria:
Patients will be excluded from the study for any of the following reasons:
- Treatment within the last 30 days with any investigational drug.
- Concurrent administration of any other tumour therapy, including cytotoxic chemotherapy, hormonal therapy, and immunotherapy.
- Major surgery within 28 days of study drug administration.
- Active infection that in the opinion of the investigator would compromise the patient's ability to tolerate therapy.
- Pregnancy.
- Breast feeding.
- Serious concomitant disorders that would compromise the safety of the patient or compromise the patient's ability to complete the study, at the discretion of the investigator.
- Active bleeding disorder or bleeding site.
- Non-healing wound.
- Poorly controlled diabetes mellitus.
- Second primary malignancy that is clinically detectable at the time of consideration for study enrolment.
- Symptomatic brain metastasis.
- History of significant neurological or mental disorder, including seizures or dementia,
- History of autoimmune disease or use of gamma immunoglobulin
- Unable to comply with study procedures
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT06027983
Contact: Soo Chin Lee | +65 6908 2222 | soo_chin_lee@nuhs.edu.sg |
Principal Investigator: | Soo Chin Lee | National University Hospital, Singapore |
Responsible Party: | National University Hospital, Singapore |
ClinicalTrials.gov Identifier: | NCT06027983 |
Other Study ID Numbers: |
ACEHER2 |
First Posted: | September 7, 2023 Key Record Dates |
Last Update Posted: | October 30, 2023 |
Last Verified: | June 2023 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Product Manufactured in and Exported from the U.S.: | No |
Breast Neoplasms Neoplasms by Site Neoplasms Breast Diseases Skin Diseases |
Trastuzumab Fludarabine Antineoplastic Agents, Immunological Antineoplastic Agents |